Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD

Conditions

Cardiovascular Diseases

Brief summary

To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.

Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R.

2017-08-0124 citations

10.1007/s40261-017-0533-0

Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients

Manon C. Stam‐Slob, Yolanda van der Graaf, Jacoba P. Greving, Jannick A N Dorresteijn, Frank L.J. Visseren

Journal of the American Heart Association2017-02-0222 citations

10.1161/jaha.116.004648

Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes.

Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A, TNT, CARDS and IDEAL Steering Committees and Investigators.

2016-07-3017 citations

10.1016/j.ijcard.2016.07.201

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

Robert M. Stoekenbroek, S. Matthijs Boekholdt, Rana Fayyad, Rachel Laskey, Matti J. Tikkanen et al. (7 authors)

Heart2015-01-1645 citations

10.1136/heartjnl-2014-306906

High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect.

Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL.

2013-05-1430 citations

10.1161/circulationaha.112.000712

Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients.

Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA.

2010-02-0317 citations

10.1161/circgenetics.109.897793

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.

2005-11-011,059 citations

10.1001/jama.294.19.2437

Interventions

DRUGatorvastatin

DRUGsimvastatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 80 Years

Healthy volunteers

No

Inclusion criteria

* Previous myocardial infarction

Exclusion criteria

* Women who are breast feeding or are pregnant

Design outcomes

Primary

Measure	Time frame
Time to of a major coronary event: 1) non-fatal acute myocardial infarction 2) coronary death 3) resuscitated cardiac arrest	—

Secondary

Measure	Time frame
1) Time to any CHD event, 2) Time to Hospitalization with primary diagnosis of CHF, 3) Time to Cerbrovascular Event, 4) Time to PAD, 5) Time to any CV event and 6) All Cause Mortality	—

Countries

Denmark, Finland, Iceland, Netherlands, Norway, Sweden

Outcome results

None listed